advanced search

Welcome: Guest

log in

0 items in basket Total: £0
$0 / €0

View Basket

US Market for Interventional Cardiology 2008

Publication Date November 2007
Publisher iData Research
Product Type Report
Pages 235
ISBN Number not applicable
Product Code IDR00079
Buy this product or for assistance call +44 20 7060 7474
PDF £4,505.00$7494 | €5042
PRINT £4,205.00$6995 | €4706
FAX Order above formats by FAX

Summary

In 2007, the U.S. market for interventional cardiology devices was valued at almost $5 billion, experiencing a small increase over 2006. Drug-eluting stents were the largest segment of the market, followed by coronary closure devices, percutaneous transluminal coronary angioplasty (PTCA) balloons, bare-metal stents, embolic protection devices, interventional guidewires, diagnostic catheters, intravascular

ultrasound (IVUS) catheters, and interventional catheters, as depicted in Chart 1-1. From 2007, the U.S. market for interventional cardiology is expected to decrease, with the market limited by the safety concerns over drug-eluting stents.

Content

  • I
  • LIST OF FIGURES
  • LIST OF CHARTS
  • EXECUTIVE SUMMARY
    • 1.1 U.S. MARKET FOR INTERVENTIONAL CARDIOLOGY DECES
    • 1.2 BARE-METAL AND DRUG-ELUTING
    • 1.3 PTCA AND CUTTING BALLOONS
    • 1.4 IVUS CATHETERS
    • 1.5 INTERVENTIONAL CATHETERS
    • 1.6 INTERVENTIONAL GUIDEWIRES
    • 1.7 BALLOON-INFLATION SYRINGES AND ANGIOPLASTY KITS
    • 1.8 EMBOLIC PROTECTION DECES
    • 1.9 ATHERECTOMY DECES
    • 1.10 BRACHYTHERAPY CATHETERS
    • 1.11 CHRONIC TOTAL OCCLUSION CROSSERS
    • 1.12 THROMBECTOMY DECES
    • 1.13 INTRODUCER SHEATHS: CORONARY AND PERIPHERAL MARKETS
    • 1.14 VASCULAR CLOSURE DECES
    • 1.15 DIAGNOSTIC CORONARY CATHETERS AND GUIDEWIRES
    • 1.16 LEADING COMPETITORS
    • 1.17 POTENTIAL MARKETS
  • RESEARCH METHODOLOGY
    • 2.1 RESEARCH SCOPE
    • 2.2 IDATA'S 9 STEP METHODOLOGY
    • 2.2.1 Step 1: Project Initiation & Team Selection
    • 2.2.2 Step 2: Prepare Data Systems and Perform Secondary Research
    • 2.2.3 Step 3: Preparation for Interews & Survey Design
    • 2.2.4 Step 4: Performing Primary Research
    • 2.2.5 Step 5: Research Analysis: Establishing Baseline Estimates
    • 2.2.6 Step 6: Market Forecasting
    • 2.2.7 Step 7: Identify Strategic Opportunities
    • 2.2.8 Step 8: Final Reew and Market Release
    • 2.2.9 Step 9: Customer Feedback and Market Monitoring
    • U.S. MARKET FOR INTERVENTIONAL CARDIOLOGY DECES
    • 3.1 INTRODUCTION
    • 3.2 OVEREW OF THE MARKET
    • 3.3 MARKET SEGMENTED BY DECE TYPE
    • 3.4 TREND ANALYSIS BY MARKET SEGMENT
    • 3.5 MARKET DRIVERS
    • 3.5.1 Drug-Eluting Stents
    • 3.5.2 New Diagnostic Technologies
    • 3.5.3 Demographics
    • 3.6 MARKET LIMITERS
    • 3.6.1 Late-Stent Thrombosis
    • 3.6.2 Chronic Total Occlusions
    • 3.6.3 Price Competition
    • 3.7 COMPETITIVE ANALYSIS
    • 3.8 MARKET CONCENTRATION
    • 3.9 MERGERS AND ACQUISITIONS
    • 3.9.1 Boston Scientific Acquires Guidant
    • 3.9.2 Abbott Laboratories Acquires Guidant's Interventional Cardiology Dision
    • 3.9.3 Johnson & Johnson Agrees to Acquire Conor Medsystems
    • 3.9.4 Future Acquisitions
    • 3.10 LITIGATION ISSUES
    • 3.11 POTENTIAL MARKETS
    • BARE-METAL AND DRUG-ELUTING
    • 4.1 INTRODUCTION
    • 4.2 POPULATION AT RISK
    • 4.3 PROCEDURE NUMBERS
    • 4.4 MARKET ANALYSIS & FORECAST
    • 4.5 UNITS SOLD
    • 4.6 STENT MARKET BY DELIVERY PLATFORM
    • 4.7 STENT MARKET BY SIZE
    • 4.8 BARE-METAL STENT MARKET
    • 4.8.1 Market Analysis & Forecast
    • 4.8.2 Competite Analysis
    • 4.9 DRUG-ELUTING STENT MARKET
    • 4.9.1 Market Analysis & Forecast
    • 4.9.2 Competite Analysis
    • 4.10 MARKET DRIVERS AND LIMITERS
    • 4.10.1 Market Drers
    • 4.10.2 The COURAGE Study
    • 4.10.3 Market Limiters
    • 4.11 NEW MARKET PARTICIPANTS
    • 4.11.1 Abbott Laboratories
    • 4.11.2 Medtronic
    • 4.11.3 Conor Medsystems
    • 4.11.4 Xtent Inc
    • 4.11.5 Biosensors International
    • 4.11.6 B. Braun
    • 4.11.7 MIV Therapeutics Inc
  • PTCA AND CUTTING BALLOON CATHETERS
    • 5.1 INTRODUCTION
    • 5.1.1 The Problem of Restenosis
    • 5.1.2 Conventional and Cutting Balloons
    • 5.2 MARKET ANALYSIS & FORECAST
    • 5.3 MARKET FOR PTCA BALLOONS
    • 5.3.1 Units Sold
    • 5.3.2 Market Analysis & Forecast
    • 5.3.3 Competite Analysis
    • 5.4 MARKET FOR CUTTING BALLOONS
    • 5.4.1 Dece Penetration
    • 5.4.2 Market Analysis & Forecast
    • 5.4.3 Competite Analysis
    • 5.5 MARKET DRIVERS AND LIMITERS
    • 5.5.1 Market Drers
    • 5.5.2 Market Limiters
    • 5.6 NEW TECHNOLOGIES DRUG-COATED BALLOON CATHETERS
  • BALLOON-INFLATION SYRINGES
    • 6.1 MARKET ANALYSIS & FORECAST
    • 6.2 MARKET DRIVERS AND LIMITERS
    • 6.2.1 Market Drers
    • 6.2.2 Market Limiters
    • 6.3 COMPETITIVE ANALYSIS
  • ANGIOPLASTY KITS
    • 7.1 MARKET ANALYSIS & FORECAST
    • 7.2 MARKET DRIVERS AND LIMITERS
    • 7.2.1 Market Drers
    • 7.2.2 Market Limiters
    • 7.3 COMPETITIVE ANALYSIS
  • IVUS CATHETERS
    • 8.1 INTRODUCTION
    • 8.1.1 Pre-Stenting Application
    • 8.1.2 Post-Stenting Examination
    • 8.2 MARKET ANALYSIS & FORECAST
    • 8.3 PENETRATION RATE
    • 8.4 MARKET DRIVERS AND LIMITERS
    • 8.4.1 Market Drers
    • 8.4.2 Market Limiters
    • 8.5 COMPETITIVE ANALYSIS
  • INTERVENTIONAL CATHETERS
    • 9.1 INTRODUCTION
    • 9.1.1 Support and Guiding Catheters
    • 9.1.2 Important Characteristics
    • 9.2 MARKET ANALYSIS & FORECAST
    • 9.3 UNITS SOLD
    • 9.4 INTERVENTIONAL GUIDING CATHETERS MARKET
    • 9.4.1 Market Analysis & Forecast
    • 9.5 INTERVENTIONAL SUPPORT CATHETERS MARKET
    • 9.5.1 Market Analysis & Forecast
    • 9.6 MARKET DRIVERS AND LIMITERS
    • 9.6.1 Market Drers
    • 9.6.2 Market Limiters
    • 9.7 COMPETITIVE ANALYSIS
  • INTERVENTIONAL GUIDEWIRES
    • 10.1 INTRODUCTION
    • 10.1.1 Conventional and Specialty Guidewires
    • 10.1.2 Material and Fabrication
    • 10.2 MARKET ANALYSIS & FORECAST
    • 10.3 UNITS SOLD
    • 10.4 CONVENTIONAL GUIDEWIRES MARKET
    • 10.5 SPECIALIZED GUIDEWIRES MARKET
    • 10.6 MARKET DRIVER AND LIMITERS
    • 10.6.1 Market Drers
    • 10.6.2 Market Limiters
    • 10.7 COMPETITIVE ANALYSIS
  • EMBOLIC PROTECTION DECES
    • 11.1 INTRODUCTION
    • 11.1.1 Saphenous Vein Grafts
    • 11.1.2 Protection Mechanism
    • 11.2 MARKET ANALYSIS & FORECAST
    • 11.3 PENETRATION RATE
    • 11.4 TREND ANALYSIS
    • 11.5 MARKET DRIVERS AND LIMITERS
    • 11.5.1 Market Drers
    • 11.5.2 Market Limiters
    • 11.6 COMPETITIVE ANALYSIS
    • 11.6.1 Leading Products
    • 11.6.2 Market Share
  • ATHERECTOMY DECES
    • 12.1 INTRODUCTION
    • 12.1.1 Atherectomy
    • 12.1.2 Technologies
    • 12.2 MARKET ANALYSIS & FORECAST
    • 12.3 PENETRATION RATE
    • 12.4 TREND ANALYSIS
    • 12.5 MARKET DRIVERS AND LIMITERS
    • 12.5.1 Market Drers
    • 12.5.2 Market Limiters
    • 12.6 COMPETITIVE ANALYSIS
  • BRACHYTHERAPY CATHETERS
    • 13.1 INTRODUCTION
    • 13.1.1 The Introduction of Drug-Eluting Stents
    • 13.2 MARKET ANALYSIS & FORECAST
    • 13.3 PENETRATION RATE
    • 13.4 MARKET DRIVERS AND LIMITERS
    • 13.4.1 Market Drers
    • 13.4.2 Market Limiters
    • 13.5 COMPETITIVE ANALYSIS
  • THROMBECTOMY DECES
    • 14.1 INTRODUCTION
    • 14.1.1 Thrombosis and Drug-Eluting Stents
    • 14.2 MARKET ANALYSIS & FORECAST
    • 14.3 PENETRATION RATE
    • 14.4 TREND ANALYSIS
    • 14.5 MARKET DRIVERS AND LIMITERS
    • 14.5.1 Market Drers
    • 14.5.2 Market Limiters
    • 14.6 COMPETITIVE ANALYSIS
  • CHRONIC TOTAL OCCLUSION CROSSERS
    • 15.1 INTRODUCTION
    • 15.1.1 Crossing Chronic Total Occlusions
    • 15.1.2 Specialized Deces
    • 15.2 POTENTIAL MARKET
    • 15.3 MARKET ANALYSIS & FORECAST
    • 15.4 PENETRATION RATE
    • 15.5 TREND ANALYSIS
    • 15.6 MARKET DRIVERS AND LIMITERS
    • 15.6.1 Market Drers
    • 15.6.2 Market Limiters
    • 15.7 COMPETITIVE ANALYSIS
  • INTRODUCER SHEATHS: CORONARY AND PERIPHERAL MARKETS
    • 16.1 INTRODUCTION
    • 16.2 MARKET ANALYSIS & FORECAST
    • 16.3 CORONARY MARKET
    • 16.3.1 Units Sold
    • 16.3.2 Market Analysis & Forecast
    • 16.4 PERIPHERAL MARKET
    • 16.4.1 Units Sold
    • 16.4.2 Market Analysis & Forecast
    • 16.5 MARKET DRIVERS AND LIMITERS
    • 16.5.1 Market Drers
    • 16.5.2 Market Limiters
    • 16.6 COMPETITIVE ANALYSIS
  • VASCULAR CLOSURE DECES
    • 17.1 INTRODUCTION
    • 17.1.1 Manual Compression
    • 17.1.2 Invase and Non-Invase Deces
    • 17.2 MARKET ANALYSIS & FORECAST
    • 17.3 PENETRATION RATE
    • 17.3.1 Diagnostic Procedures
    • 17.3.2 Interventional Procedures
    • 17.4 MARKET DRIVERS AND LIMITERS
    • 17.4.1 Market Drers
    • 17.4.2 Market Limiters
    • 17.5 COMPETITIVE ANALYSIS
  • DIAGNOSTIC CATHETERS AND GUIDEWIRES
    • 18.1 INTRODUCTION
    • 18.1.1 Coronary Angiography
    • 18.2 MARKET ANALYSIS & FORECAST
    • 18.3 DIAGNOSTIC CATHETERS
    • 18.3.1 Market Analysis & Forecast
    • 18.3.2 Units Sold
    • 18.3.3 Units Sold Segmented by Size
    • 18.3.4 Competite Analysis
    • 18.4 DIAGNOSTIC GUIDEWIRES
    • 18.4.1 Market Analysis & Forecast
    • 18.4.2 Units Sold
    • 18.4.3 Competite Analysis
    • 18.5 MARKET DRIVERS AND LIMITERS
    • 18.5.1 Market Drers
    • 18.5.2 Market Limiters
  • POTENTIAL MARKETS
    • 19.1 INTRODUCTION
    • 19.1.1 PFOs, ASDs, and VSDs
    • 19.1.2 Percutaneous Mitral Valve Repair (PMVR)
    • 19.1.3 Screening and Treatment of Vulnerable Plaque
    • 19.2 OVEREW OF POTENTIAL MARKETS
    • PFO, ASD, AND VSD DECES
    • 20.1 TARGET POPULATION
    • 20.2 POTENTIAL MARKET
    • 20.2.1 Market Analysis & Forecast: Best-Case Scenario
    • 20.2.2 Revenue Probability
    • 20.3 COMPETITIVE ANALYSIS
    • 20.3.1 AGA Medical
    • 20.3.2 NMT Medical
    • 20.3.3 St. Jude Medical
    • 20.3.4 W.L. Gore
    • 20.3.5 Cardia Inc
    • 20.3.6 Cierra Inc
  • PERCUTANEOUS MITRAL VALVE REPAIR DECES
    • 21.1 TARGET POPULATION
    • 21.2 POTENTIAL MARKET
    • 21.2.1 Market Analysis & Forecast: Best-Case Scenario
    • 21.2.2 Revenue Probability
    • 21.3 COMPETITIVE ANALYSIS
    • 21.3.1 Evalve
    • 21.3.2 Edward Lifesciences
    • 21.3.3 Cardiac Dimensions
    • 21.3.4 Mitralign
    • 21.3.5 Viacor
  • VULNERABLE PLAQUE DECES
    • 22.1 TARGET POPULATION
    • 22.2 POTENTIAL MARKET: BEST-CASE SCENARIO
    • 22.3 SCREENING MARKET
    • 22.3.1 Market Analysis & Forecast: Best-Case Scenario
    • 22.3.2 Revenue Probability
    • 22.4 INTERVENTIONAL MARKET
    • 22.4.1 Market Analysis & Forecast: Best-Case Scenario
    • 22.4.2 Revenue Probability
    • 22.5 COMPETITIVE ANALYSIS
    • 22.5.1 Volcano Therapeutics
    • 22.5.2 Bristol-Myers Squibb
    • 22.5.3 Medeikon
    • 22.5.4 Cryocath
    • 22.5.5 Miravant Technologies
    • 22.5.6 Boston Scientific
    • 22.5.7 Abbott Laboratories
    • 22.5.8 Cordis
    • 22.5.9 Medtronic
  • ABBREATIONS
  • LIST OF FIGURES
    • Figure 3-1 U.S. Market for Interventional Cardiology Segmented by Dece Type,2003 2013
    • Figure 3-2 Trend Analysis by Market Segment, Growth Rates of the U.S. Market for Interventional Cardiology, 2003 2013
    • Figure 3-3 Market Drers, U.S. Market for Interventional Cardiology, 2006
    • Figure 3-4 Market Limiters, U.S. Market for Interventional Cardiology, 2006
    • Figure 3-5 Leading Competitors by Market Segment, U.S. Market for Interventional Cardiology, 2006
    • Figure 3-6 Market Concentration based on the Herfindahl Index, U.S. Market for Interventional Cardiology, 2003 2013
    • Figure 3-7 Potential U.S. Markets for Interventional Cardiology Deces
    • Figure 4-1 Angiography and Angioplasty Procedures, U.S., 2003 2013
    • Figure 4-2 U.S. Market for Coronary Stents by Type, 2003 2013
    • Figure 4-3 Units Sold, U.S. Market for Coronary Stents, 2003 2013
    • Figure 4-4 U.S. Market for Coronary Stents by Delery Platform, Units Sold, 2003 2013
    • Figure 4-5 U.S. Market for Coronary Stents by Size, Units Sold, 2006
    • Figure 4-6 U.S. Market for Bare-Metal Stents, 2003 2013
    • Figure 4-7 Leading Competitors, U.S. Market for Bare-Metal Stents, 2006
    • Figure 4-8 U.S. Market for Drug-Eluting Stents, 2003 2013
    • Figure 4-9 Leading Competitors, U.S. Market for Drug-Eluting Stents, 2006
    • Figure 4-10 Market Drers, U.S. Market for Coronary Stents, 2006
    • Figure 4-11 Market Limiters, U.S. Market for Coronary Stents, 2006
    • Figure 4-12 New Market Participants, U.S. Market for Coronary Stents, 2006
    • Figure 5-1 U.S. Market for PTCA and Cutting Balloon Catheters, 2003 2013
    • Figure 5-2 Units Sold, U.S. Market for PTCA Balloon Catheters, 2003 2013
    • Figure 5-3 U.S. Market for PTCA Balloon Catheters, 2003 2013
    • Figure 5-4 Leading Competitors, U.S. Market for PTCA Balloon Catheters, 2006
    • Figure 5-5 Units Sold, U.S. Market for Cutting Balloon Catheters, 2003 2013
    • Figure 5-6 U.S. Market for Cutting Balloon Catheters, 2003 2013
    • Figure 5-7 Leading Competitor, U.S. Market for Cutting Balloon Catheters, 2006
    • Figure 5-8 Market Drers and Limiters, U.S. Market for PTCA and Cutting Balloon Catheters, 2006
    • Figure 6-1 U.S. Market for Balloon-Inflation Syringes, 2003 2013
    • Figure 6-2 Market Drers and Limiters, U.S. Market for Balloon-Inflation Syringes,2006
    • Figure 6-3 Leading Competitors, Market for Balloon-Inflation Syringes, 2006
    • Figure 7-1 U.S. Market for Angioplasty Accessory Kits, 2003 2013
    • Figure 7-2 Market Drers and Limiters, U.S. Market for Angioplasty Accessory Kits,2003 2013
    • Figure 7-3 Leading Competitors, U.S. Market for Angioplasty Accessory Kits, 2003 2013
    • Figure 8-1 U.S. Market for IVUS Catheters, 2003 2013
    • Figure 8-2 Penetration Rate, U.S. Market for IVUS Catheters, 2003 2013
    • Figure 8-3 Market Drers and Limiters, U.S. Market for IVUS Catheters, 2003 2013
    • Figure 8-4 Leading Competitors, U.S. Market for IVUS Catheters, 2003 2013
    • Figure 9-1 U.S. Market for Interventional Coronary Catheters by Dece Type, 2003 2013
    • Figure 9-2 Units Sold, U.S. Market for Interventional Coronary Catheters, 2003 2013
    • Figure 9-3 U.S. Market for Interventional Guiding Catheters, 2003 2013
    • Figure 9-4 U.S. Market for Interventional Support Catheters, 2003 2013
    • Figure 9-5 Market Drers and Limiters, U.S. Market for Interventional Coronary Catheters, 2006
    • Figure 9-6 Leading Competitors, U.S. Market for Interventional Coronary Catheters,2006
    • Figure 10-1 U.S. Market for Interventional Coronary Guidewires by Dece Type,2003 2013
    • Figure 10-2 Units Sold, U.S. Market for Interventional Coronary Guidewires, 2003 2013
    • Figure 10-3 U.S. Market for Interventional Coronary Conventional Guidewires, 2003 2013
    • Figure 10-4 U.S. Market for Interventional Coronary Specialized Guidewires, 2003 2013
    • Figure 10-5 Market Drers and Limiters, U.S. Market for Interventional Coronary Guidewires, 2006
    • Figure 10-6 Leading Competitors, U.S. Market for Interventional Coronary Guidewires, 2006
    • Figure 11-1 U.S. Market for Coronary Embolic Protection Deces, 2003 2013
    • Figure 11-2 Penetration Rate, U.S. Market for Coronary Embolic Protection Deces,2003 2013
    • Figure 11-3 Market Drers and Limiters, U.S. Market for Coronary Embolic Protection Deces, 2006
    • Figure 11-4 Leading Competitors, U.S. Market for Coronary Embolic Protection Deces, 2006
    • Figure 12-1 U.S. Market for Coronary Atherectomy Deces, 2003 2013
    • Figure 12-2 Penetration Rate, U.S. Market for Coronary Atherectomy Deces, 2003 2013
    • Figure 12-3 Market Drers and Limiters, U.S. Market for Coronary Artherectomy Deces, 2006
    • Figure 12-4 Leading Competitors, U.S. Market for Coronary Atherectomy Deces,2006
    • Figure 13-1 U.S. Market for Coronary Brachytherapy Catheters, 2003 2013
    • Figure 13-2 Penetration Rate, U.S. Market for Coronary Brachytherapy Catheters,2003 2013
    • Figure 13-3 Market Drers and Limiters, U.S. Market for Coronary Brachytherapy Catheters, 2006
    • Figure 13-4 Leading Competitors, U.S. Market for Coronary Brachytherapy Catheters,2006
    • Figure 14-1 U.S. Market for Coronary Thrombectomy Deces, 2003 2013
    • Figure 14-2 Penetration Rate, U.S. Market for Coronary Thrombectomy Deces, 2003 2013
    • Figure 14-3 Market Drers and Limiters, U.S. Market for Coronary Thrombectomy Deces, 2006
    • Figure 14-4 Leading Competitors, U.S. Market for Coronary Thrombectomy Deces,2006
    • Figure 15-1 Potential Market for Chronic Total Occlusion Crossers, U.S. Market for Interventional Cardiology, 2003 2013
    • Figure 15-2 U.S. Market for Coronary Chronic Total Occlusion Crossers, 2003 2013
    • Figure 15-3 Penetration Rate, U.S. Market for Coronary Chronic Total Occlusion Crossers, 2003 2013
    • Figure 15-4 Market Drers and Limiters, U.S. Market for Coronary Chronic Total Occlusion Crossers, 2006
    • Figure 15-5 Market Players, U.S. Market for Coronary Chronic Total Occlusion Crossers, 2006
    • Figure 16-1 U.S. Peripheral and Coronary Markets for Introducer Sheaths, 2003 2013
    • Figure 16-2 Units Sold, U.S. Coronary Market for Introducer Sheaths, 2003 2013
    • Figure 16-3 U.S. Coronary Market for Introducer Sheaths, 2003 2013
    • Figure 16-4 Units Sold, U.S. Peripheral Market for Introducer Sheaths, 2003 2013
    • Figure 16-5 U.S. Peripheral Market for Introducer Sheaths, 2003 2013
    • Figure 16-6 Market Drers and Limiters, U.S. Market for Introducer Sheaths, 2006
    • Figure 16-7 Leading Competitors, U.S. Market for Introducer Sheaths, 2006
    • Figure 17-1 U.S. Market for Coronary Vascular Closure Deces (Invase and Non-Invase), 2003 2013
    • Figure 17-2 Penetration Rate, U.S. Market for Coronary Vascular Closure Deces(Invase and Non-Invase), 2003 2013
    • Figure 17-3 Market Drers, U.S. Market for Coronary Vascular Closure Deces,2006
    • Figure 17-4 Market Limiters, U.S. Market for Coronary Vascular Closure Deces,2006
    • Figure 17-5 Leading Competitors, U.S. Market for Coronary Vascular Closure Deces, 2006
    • Figure 18-1 U.S. Market for Diagnostic Coronary Catheters and Guidewires, 2003 2013
    • Figure 18-2 U.S. Market for Diagnostic Coronary Catheters, 2003 2013
    • Figure 18-3 Units Sold, U.S. Market for Diagnostic Coronary Catheters, 2003 2013
    • Figure 18-4 Units Sold Segmented by Size, U.S. Market for Diagnostic Coronary Catheters, 2003 2013
    • Figure 18-5 Leading Competitors, U.S. Market for Diagnostic Coronary Catheters,2006
    • Figure 18-6 U.S. Market for Diagnostic Coronary Guidewires, 2003 2013
    • Figure 18-7 Units Sold, U.S. Market for Diagnostic Coronary Guidewires, 2003 2013
    • Figure 18-8 Leading Competitors, U.S. Market for Diagnostic Coronary Guidewires,2006
    • Figure 18-9 Market Drers and Limiters, U.S. Market for Diagnostic Coronary Catheters and Guidewires, 2006
    • Figure 19-1 Potential U.S. Markets for Interventional Cardiology, Best-Case Scenario, 2008 2013
    • Figure 20-1 Target Population, Potential U.S. Market for PFO, ASD, and VSD Deces, 2003 2013
    • Figure 20-2 Potential U.S. Market for PFO, ASD, and VSD Deces, Best-Case Scenario, 2003 2013
    • Figure 20-3 Total Revenue, Potential U.S. Market for PFO, ASD, and VSD Deces, Best-Case Scenario, 2008 2013
    • Figure 20-4 Market Players, Potential U.S. Market for PFO, ASD, and VSD Deces,2008 2013
    • Figure 21-1 Target Population, Potential U.S. Market for PMVR Deces, 2009 2013
    • Figure 21-2 Potential U.S. Market for PMVR Deces, Best-Case Scenario, 2009 2013
    • Figure 21-3 Total Revenue, Potential U.S. Market for PMVR Deces, Best- Case Scenario, 2009 2013
    • Figure 21-4 Market Players, Potential U.S. Market for PMVR Deces, 2009 2013
    • Figure 22-1 Target Population, Potential U.S. Market for Vulnerable Plaque, 2009 2013
    • Figure 22-2 Potential U.S. Market for Vulnerable Plaque, Best-Case Scenario, 2009 2013
    • Figure 22-3 Potential U.S. Market for Vulnerable Plaque Screening Deces, Best- Case Scenario, 2009 2013
    • Figure 22-4 Total Revenue, Potential U.S. Market for Vulnerable Plaque Screening Deces, Best-Case Scenario, 2009 2013
    • Figure 22-5 Potential U.S. Market for Vulnerable Plaque Interventional Deces, Best- Case Scenario, 2009 2013
    • Figure 22-6 Total Revenue, Potential U.S. Market for Vulnerable Plaque Interventional Deces, Best-Case Scenario, 2009 2013
    • Figure 22-7 Market Players, Potential U.S. Market for Vulnerable Plaque Deces,2009 2013
  • LIST OF CHARTS
    • Chart 1-1 U.S. Market for Interventional Cardiology by Segment, 2006
    • Chart 1-2 U.S. Market for Coronary Stents, 2003 2013
    • Chart 1-3 U.S. Market for PTCA and Cutting Balloons, 2003 2013
    • Chart 1-4 U.S. Market for IVUS Catheters, 2003 2013
    • Chart 1-5 U.S. Market U.S. Market for Diagnostic Coronary Catheters and Guidewires
    • Chart 1-6 Leading Competitors, U.S. Market for Interventional Cardiology, 2006
    • Chart 1-7 Potential U.S. Markets for Interventional Cardiology, 2003 2013
    • Chart 3-1 Market for Interventional Cardiology, 2003 2013
    • Chart 3-2 U.S. Market for Interventional Cardiology Segmented by Dece Type, 2006
    • Chart 3-3 Trend Analysis by Market Segment, U.S. Market for Interventional Cardiology, 2003 2013
    • Chart 3-4 Leading Competitors, U.S. Market for Interventional Cardiology, 2006
    • Chart 3-5 Market Concentration based on the Herfindahl Index, U.S. Market for Interventional Cardiology, 2003 2013
    • Chart 4-1 Population at Risk, U.S. Market for Interventional Cardiology, 2003 2013
    • Chart 4-2 Age Group Most Likely to Undergo Cardiac Intervention, U.S. Market for Intervention Cardiology, 2003 2013
    • Chart 4-3 Angioplasty and Angiography Procedures, U.S., 2003 2013
    • Chart 4-4 U.S. Market for Coronary Stents by Type, 2003 2013
    • Chart 4-5 U.S. Market for Coronary Stents by Type, Units Sold, 2003 2013
    • Chart 4-6 U.S. Market for Coronary Stents by Delery Platform, Units Sold, 2003 2013
    • Chart 4-7 U.S. Market for Coronary Stents by Size, Units Sold, 2006
    • Chart 4-8 U.S. Market for Bare-Metal Stents, 2003 2013
    • Chart 4-9 U.S. Market for Drug-Eluting Stents, 2003 2013
    • Chart 5-1 U.S. Market for PTCA and Cutting Balloon Catheters, 2003 2013
    • Chart 5-2 U.S. Market for PTCA Balloon Catheters, 2003 2013
    • Chart 5-3 U.S. Market for Cutting Balloon Catheters, 2003 2013
    • Chart 6-1 U.S. Market for Balloon-Inflation Syringes, 2003 2013
    • Chart 6-2 Leading Competitors, Market for Balloon-Inflation Syringes, 2006
    • Chart 7-1 U.S. Market for Angioplasty Accessory Kits, 2003 2013
    • Chart 8-1 U.S. Market for IVUS Catheters, 2003 2013
    • Chart 9-1 U.S. Market for Interventional Coronary Catheters by Dece Type, 2003 2013
    • Chart 10-1 U.S. Market for Interventional Coronary Guidewires by Dece Type, 2003 2013
    • Chart 10-2 U.S. Market for Interventional Coronary Guidewires by Dece Type, Units Sold, 2003 2013
    • Chart 11-1 U.S. Market for Coronary Embolic Protection Deces, 2003 2013
    • Chart 11-2 CAGRs, U.S. Markets for Peripheral and Coronary Embolic Protection Deces, 2004 2011
    • Chart 12-1 U.S. Market for Coronary Atherectomy Deces, 2003 2013
    • Chart 12-2 CAGRs, U.S. Markets for Peripheral and Coronary Atherectomy Deces,2004 2011
    • Chart 13-1 U.S. Market for Coronary Brachytherapy Catheters, 2003 2013
    • Chart 14-1 U.S. Market for Coronary Thrombectomy Deces, 2003 2013
    • Chart 14-2 CAGRs, U.S. Markets for Peripheral and Coronary Thrombectomy Deces,2004 2011
    • Chart 15-1 U.S. Market for Coronary Chronic Total Occlusion Crossers, 2003 2013
    • Chart 15-2 Penetration Rate, U.S. Market for Coronary Chronic Total Occlusion Crossers, 2003 2013
    • Chart 15-3 CAGRs, U.S. Markets for Peripheral and Coronary Chronic Total Occlusion Crossers, 2004 2011
    • Chart 16-1 U.S. Peripheral and Coronary Markets for Introducer Sheaths, 2003 2013
    • Chart 17-1 U.S. Market for Coronary Vascular Closure Deces, (Invase and Non- Invase), 2003 2013
    • Chart 18-1 U.S. Market for Diagnostic Coronary Catheters and Guidewires, 2003 2013
    • Chart 18-2 Units Sold Segmented by Size, U.S. Market for Diagnostic Coronary Catheters, 2003 2013
    • Chart 19-1 Current and Potential Markets for Interventional Cardiology in the U.S., Best- Case Scenario, 2003 2013
    • Chart 20-1 Revenue Probability, Potential U.S. Market for PFO, ASD, and VSD Deces, 2008 2013
    • Chart 21-1 Revenue Probability, Potential U.S. Market for PMVR Deces, 2009 2013
    • Chart 22-1 Potential U.S. Market for Vulnerable Plaque, Best-Case Scenario, 2009 2013
    • Chart 22-2 Revenue Probability, Potential U.S. Market for Vulnerable Plaque Screening Deces, 2009 2013
    • Chart 22-3 Revenue Probability, Potential U.S. Market for Vulnerable Plaque Interventional Deces, 2009 2013

back to top

Delivery Details

PDF:Dleivered by email within 4 to 24 hours during UK business hours (Mon-Fri)

PRINT/CD-ROM:Despatched by courier if outside Canada within 2 to 6 working days.

Ask a question about this product

Need help finding the right product?

Product features / use
Scope Comprehensive Overview yes
Data Detailed Market Forecasts yes
Profiles Profiles of Key Companies yes
Features Primary Research Data yes
Related Products

Industry Events

Innovations in Oncology Drug Discovery, Development & Delivery

01 Dec 09 to 01 Dec 09
N/A, UK
view summary >>

Best Practice in Phase IV Clinical & Observational Research

03 Dec 09 to 04 Dec 09
Prague, Czech Republic
view summary >>

2nd International Conference on Drug Discovery and Therapy

01 Feb 10 to 04 Feb 10
Dubai, United Arab Emirates
view summary >>

Pharma & Healthcare

Customer Services

How To Buy
Formats & Delivery
Terms & Conditions
Account Options
Login/Register

call +44 (0) 20 7060 7474
or email us

Resources

Why Report Buyer?
Advertising/Affiliates
View Our Publishers
News
About Us
Meet Us
Jobs
Contact Us
Categories and Subcategories

Post it

Del.icio.us
StumbleUpon
Reddit

logo: AddThis